News

Deal Announcements

Bellicum Pharma Nets Series A Venture Capital

Wednesday, November 4, 2009 5:30:00 AM PDT | VentureDeal Staff
Houston, Texas  --  Cancer pharmaceutical company Bellicum Pharmaceuticals has landed $4.5 million in its series A round of venture capital investment.

Bellicum says that it is utilizing knowledge of the signaling pathways that regulate the immune response in order to develop therapeutic vaccines for cancer and chronic infectious diseases.

Investors in the round were not disclosed.  The company said it would use the funds to complete its ongoing Phase I/IIa trial for its prostate cancer lead candidate.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1